

Clinically proven to improve glycemic outcomes in non-insulin-treated adults with T2D*1

IMMEDIATE RCT



- Multisite, open-label RCT
- Assess glycemic control and patient satisfaction




- N=116
- Adults with T2D (>6 mos.)
- Baseline A1c≥7.5%
- At least 1 non-insulin therapy




- FreeStyle Libre systems[†] + Diabetes Self-Management Education (n=58) vs. DSME alone (n=58)
- 16-week follow-up assessment

Significant improvement in glycemic control at 16 weeks with FreeStyle Libre systems[†] and DSME vs. DSME alone[‡]

Increased time in range (70 to 180 mg/dL)



Decreased time above range (>180 mg/dL)



DSME=Diabetes Self-Management Education; RCT=randomized control trial; T2D=type 2 diabetes.

*Improvement in glycemic outcomes based on the use of the FreeStyle Libre systems in addition to Diabetes Self-Management Education. †Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 2 system and FreeStyle Libre 3 system, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms. ‡Measured during the blinded CGM period during the final last two weeks of phase 1.

Reference: 1. Aronson R. *Diabetes Obes Metab* (2023): <https://doi.org/10.1111/dom.14949>.


See Important Safety Information on next page.



Abbott

Significant A1c reduction with FreeStyle Libre systems* and DSME vs. DSME alone¹

Greater A1c reduction at 16 weeks



Summary of outcomes vs. DSME alone at 16 weeks:



Increased time in range



Decreased time above range



Reduced A1c¹



Increased glucose monitoring satisfaction^{†1}



Prescribe the newest sensor in the FreeStyle Libre 3 system to your patients with T2D: **FreeStyle Libre 3 Plus sensor**

FreeStyle
Libre 3

DSME = Diabetes Self-Management Education.

*Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 2 system and FreeStyle Libre 3 system, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms. †As measured by glucose monitoring satisfaction survey (GMSS).

Reference: 1. Aronson R. *Diabetes Obes Metab* (2023): <https://doi.org/10.1111/dom.14949>.

Important Safety Information

FreeStyle Libre 14 day, FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or <https://www.FreeStyle.abbott/us-en/safety-information.html> for safety info.

The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott.

© 2024 Abbott. ADC-94211 v1.0 07/24



Abbott